RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay Inc. (AMEX:ISR) a medical isotope company focusing on the treatment of prostate and other malignant disease through use of its proprietary radioisotope technology, announced its financial results for the second quarter of fiscal 2009, ended December 31, 2008.
